Diagnos Inc New (DGNOF) 0.0806 $DGNOF
DIAGNOS Announces Amendment to its Stock Option Plan
Marketwire - Thu Sep 25, 2:00PM CDT
DIAGNOS Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today that the shareholders of the Corporation have approved an amendment to the Corporation's Stock Option Plan pursuant to which the exercise period of stock options held by Directors upon termination is extended from three (3) months to twelve (12) months.
DIAGNOS Announces Grant of Stock Options
Marketwire - Mon Sep 08, 2:01PM CDT
DIAGNOS Inc. ("DIAGNOS" or "the Corporation" (TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announces today a grant of a total of 1,537,684 stock options to the directors and officers of the Corporation as approved by the board of directors under the terms of the Corporation's stock option plan.
DIAGNOS Announces First Retinopathy Screening Unit in Turkey
Marketwire - Wed Sep 03, 9:03AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Turkey. According to the International Diabetes Federation, Turkey has a population of 74 million people with a diabetes prevalence of 14.6%, or about 10.8 million people.
DIAGNOS Announces First Retinopathy Screening Unit in Eastern Europe
Marketwire - Tue Aug 26, 10:06AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Eastern Europe.
DIAGNOS Announces First Screening Unit In Argentina
Marketwire - Thu Aug 21, 8:55AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Argentina.
DIAGNOS Announces Changes to its Board of Directors
Marketwire - Thu Jul 24, 3:01PM CDT
DIAGNOS Inc. ("DIAGNOS" or the "Corporation" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis and image processing, is pleased to announce the appointment of Mr. Lloyd M. Segal and Mr. Michael Singer as Directors of the Corporation following the resignations of Mr. Rich Baxter and Mr. Bruno Maruzzo.
DIAGNOS Announces Yet Another Expansion of Successful Program in the UAE
Marketwire - Tue Jul 22, 8:31AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today a further expansion of the agreement first announced on November 26th 2013, with the first expansion announced on March 11, 2014, to further increase screening capacity in the country.
DIAGNOS Announces Signing of Contract with Ministry of Health Owned Medical Center in the United Arab Emirates
Marketwire - Wed Jul 16, 8:30AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with Al Manama Medical Center for the deployment of a screening unit and usage of CARA in the Unite Arab Emirates, a project fully supported by the UAE Ministry of Health.
Persistence Capital Partners Files Early Warning Report
CNW Group - Thu Jul 10, 9:00PM CDT
Persistence Capital Partners LP ("PCP" , a leading Canadian private equity firm focused exclusively on investments in high growth opportunities in the healthcare field, is pleased to announce that, in connection with the completion of the three-cornered amalgamation (the "Amalgamation" among Warnex Inc. ("Warnex" and 8910979 Canada Inc., a wholly owned subsidiary of Diagnos Inc. ("Diagnos" which closed on July 8, 2014, PCP became a 13.76% shareholder of Diagnos.
DIAGNOS Completes Merger with Warnex Inc. and Announces the Issuance of Stock Warrants
Marketwire - Tue Jul 08, 2:35PM CDT
DIAGNOS Inc. ("DIAGNOS" (TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, is pleased to announce the closing of the merger (the "Merger" of Warnex Inc. ("WARNEX" with a wholly-owned subsidiary of DIAGNOS initially announced on May 5, 2014.
Shareholders of Warnex Approve the Amalgamation With Diagnos
Marketwire - Fri Jun 27, 10:42AM CDT
DIAGNOS Inc. ("DIAGNOS" (TSX VENTURE: ADK), a leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing, is pleased to announce that, at an annual and special meeting of the shareholders (the "Meeting" of Warnex Inc. ("Warnex" held yesterday, June 26, 2014, the shareholders of Warnex approved the terms of the amalgamation (the "Amalgamation" with a wholly-owned subsidiary of DIAGNOS initially announced on May 5, 2014. The Amalgamation was approved by 99.95% of Warnex shareholders voting in person or by proxy at the Meeting.
DIAGNOS Announces Amendment to its Stock Option Plan
Marketwire - Thu Sep 25, 2:00PM CDT
DIAGNOS Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today that the shareholders of the Corporation have approved an amendment to the Corporation's Stock Option Plan pursuant to which the exercise period of stock options held by Directors upon termination is extended from three (3) months to twelve (12) months. DIAGNOS Announces Grant of Stock Options
Marketwire - Mon Sep 08, 2:01PM CDT
DIAGNOS Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announces today a grant of a total of 1,537,684 stock options to the directors and officers of the Corporation as approved by the board of directors under the terms of the Corporation's stock option plan. DIAGNOS Announces First Retinopathy Screening Unit in Turkey
Marketwire - Wed Sep 03, 9:03AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Turkey. According to the International Diabetes Federation, Turkey has a population of 74 million people with a diabetes prevalence of 14.6%, or about 10.8 million people. DIAGNOS Announces First Retinopathy Screening Unit in Eastern Europe
Marketwire - Tue Aug 26, 10:06AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Eastern Europe. DIAGNOS Announces First Screening Unit In Argentina
Marketwire - Thu Aug 21, 8:55AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Argentina. DIAGNOS Announces Changes to its Board of Directors
Marketwire - Thu Jul 24, 3:01PM CDT
DIAGNOS Inc. ("DIAGNOS" or the "Corporation"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis and image processing, is pleased to announce the appointment of Mr. Lloyd M. Segal and Mr. Michael Singer as Directors of the Corporation following the resignations of Mr. Rich Baxter and Mr. Bruno Maruzzo. DIAGNOS Announces Yet Another Expansion of Successful Program in the UAE
Marketwire - Tue Jul 22, 8:31AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today a further expansion of the agreement first announced on November 26th 2013, with the first expansion announced on March 11, 2014, to further increase screening capacity in the country. DIAGNOS Announces Signing of Contract with Ministry of Health Owned Medical Center in the United Arab Emirates
Marketwire - Wed Jul 16, 8:30AM CDT
Diagnos Inc. ("DIAGNOS" or "the Corporation"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with Al Manama Medical Center for the deployment of a screening unit and usage of CARA in the Unite Arab Emirates, a project fully supported by the UAE Ministry of Health. Persistence Capital Partners Files Early Warning Report
CNW Group - Thu Jul 10, 9:00PM CDT
Persistence Capital Partners LP ("PCP"
, a leading Canadian private equity firm focused exclusively on investments in high growth opportunities in the healthcare field, is pleased to announce that, in connection with the completion of the three-cornered amalgamation (the "Amalgamation" among Warnex Inc. ("Warnex" and 8910979 Canada Inc., a wholly owned subsidiary of Diagnos Inc. ("Diagnos" which closed on July 8, 2014, PCP became a 13.76% shareholder of Diagnos. DIAGNOS Completes Merger with Warnex Inc. and Announces the Issuance of Stock Warrants
Marketwire - Tue Jul 08, 2:35PM CDT
DIAGNOS Inc. ("DIAGNOS"
(TSX VENTURE: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, is pleased to announce the closing of the merger (the "Merger" of Warnex Inc. ("WARNEX" with a wholly-owned subsidiary of DIAGNOS initially announced on May 5, 2014. Shareholders of Warnex Approve the Amalgamation With Diagnos
Marketwire - Fri Jun 27, 10:42AM CDT
DIAGNOS Inc. ("DIAGNOS"
(TSX VENTURE: ADK), a leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing, is pleased to announce that, at an annual and special meeting of the shareholders (the "Meeting" of Warnex Inc. ("Warnex" held yesterday, June 26, 2014, the shareholders of Warnex approved the terms of the amalgamation (the "Amalgamation" with a wholly-owned subsidiary of DIAGNOS initially announced on May 5, 2014. The Amalgamation was approved by 99.95% of Warnex shareholders voting in person or by proxy at the Meeting. 
